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Introduction {#sec1}
============

Phosphorylation is a pervasive form of cell signaling that orchestrates numerous processes, including metabolism, cell mobility, cell cycle, and differentiation ([@bib2], [@bib32], [@bib34]). Mass spectrometry has revealed the complexity of the phosphoproteome in pluripotent cells with great detail ([@bib19], [@bib21], [@bib23], [@bib29], [@bib32]); however, determining the biological relevance of such data remains a major challenge. Mapping the kinases responsible for a specific phosphorylation event is instructive because it places that information in the context of signaling molecules that direct biological function. Traditionally, kinase assays are performed by detecting the transfer of a radioactive phosphoryl group to a given substrate following an in vitro reaction. This method provides a direct measure of phosphorylation but necessitates the use of hazardous materials, cannot directly localize phosphorylation to a single amino acid when more than one potential site is present, and cannot multiplex kinases and substrates. Recently, a mass-spectrometric method was introduced to profile phosphorylation on synthetic peptides treated with cell lysates ([@bib38]). This method is ideal for profiling cell-type-specific phosphorylation, but does not directly determine the kinase responsible for phosphorylation. Another method assesses kinase activity but relies upon heavy isotope-labeled amino acids and is limited to testing one or two kinases at a time ([@bib26]). Several other methods have been developed to identify kinase consensus motifs or test a single kinase, but are not capable of multiplexed analysis ([@bib10], [@bib12], [@bib27], [@bib36]). Thus, there remains a pressing need for a high-throughput method to screen for kinase(s) that phosphorylate a protein of interest.

In pluripotent cells, phosphorylation has a central role in directing cell identity by relaying growth-factor signaling through key pathways (i.e., fibroblast growth factor \[FGF\] and transforming growth factor β \[TGF-β\]) ([@bib6], [@bib25], [@bib31], [@bib39]). The ultimate targets of these phosphorylation cascades are largely unknown, although recent works have provided some direction by mapping phosphorylation on the pluripotency factors OCT4 and SOX2 ([@bib3], [@bib11], [@bib21]). Conspicuously absent in these studies is NANOG, a divergent homeobox transcription factor that promotes pluripotency by binding to DNA and regulating the expression of genes related to cell fate ([@bib1], [@bib4], [@bib17], [@bib20]). In mice, overexpression of NANOG permits extended culture of undifferentiated embryonic stem cells (ESCs) in the absence of otherwise obligatory extrinsic signaling factors such as LIF and BMP4 ([@bib4], [@bib20]). Correspondingly, NANOG overexpression in human ESCs obviates the requirement for exogenous signaling through feeder cells in basal media or FGF in defined culture systems ([@bib8], [@bib35]). Hence, NANOG has a conserved role in mediating growth-factor signals that are critical for pluripotency, and, intriguingly, its overexpression is sufficient to bypass these signaling pathways to maintain the ESC state. Still, a direct link between NANOG and the signaling molecules that determine cell state remains elusive.

In mouse, NANOG protein levels are dynamic ([@bib5]), and it was recently proposed that NANOG stability is tied to phosphorylation ([@bib18]). Several studies suggested that mouse NANOG exists as a phosphoprotein ([@bib13], [@bib18], [@bib37]); however, its unique primary sequence and relatively low abundance make it difficult to purify and detect in a physiologically relevant context (i.e., without overexpression and in pluripotent cell types). As a result, there are currently no known phosphorylation sites for NANOG from human pluripotent stem cells and only a single site for endogenous mouse NANOG ([@bib13]). To address this gap, we applied high-resolution mass spectrometry to show that NANOG is heavily phosphorylated at proline-directed sites on its N terminus. To place these modifications in the context of signaling molecules, we developed the multiplexed assay for kinase specificity (MAKS), and found that ERK2 and CDK1 differentially phosphorylate NANOG in vitro.

Results {#sec2}
=======

Identification of NANOG Phosphorylation Sites {#sec2.1}
---------------------------------------------

Due to the underrepresentation of NANOG in proteomic data sets, we adapted a highly efficient purification strategy that combines high-detergent lysis with multiple forms of affinity chromatography (see [Supplemental Experimental Procedures](#app2){ref-type="sec"} available online; [@bib3]). Consistent with previous results, traditional digestion methods that utilize trypsin in preparation for mass spectrometry yielded only one phosphopeptide identification ([Figures 1](#fig1){ref-type="fig"}A and 1B). Inspection of the primary sequence for NANOG revealed that tryptic cleavage sites were tightly clustered at the center of the protein, with few sites near either termini, resulting in a limited number of peptides that were amenable to mass spectrometry ([Figure S1](#app2){ref-type="sec"}). We therefore tested several alternate proteases and found that GluC provided superior sequence coverage ([Figures 1](#fig1){ref-type="fig"}C and 1D; [@bib30]). In total, we sequenced over 40% of the endogenous NANOG protein and identified 11 phosphorylation sites (\<1% false discovery rate), nine of which localized to a single residue ([Figure 1](#fig1){ref-type="fig"}D; [Table S1](#app2){ref-type="sec"}). Note that the exact site of phosphorylation could not be distinguished between Ser22/23 and Ser68/69 by our stringent criteria, but were localized to adjacent residues in each case. [Figure 1](#fig1){ref-type="fig"}C shows a representative spectrum with a fully annotated, localized modification; all spectra were manually validated to confirm each phosphorylation site ([Figure S2](#app2){ref-type="sec"}). Many of the peptides identified from this region were multiply phosphorylated, indicating that endogenous NANOG is hyperphosphorylated in the pluripotent state.Figure 1Mass Spectrometry Identifies Phosphorylation on Human NANOG(A) NANOG phosphorylation sites.(B) The contribution to either sequence coverage or phosphorylation site identification for samples digested with trypsin or GluC.(C) Representative spectrum showing unambiguous localization of phosphorylation on Ser71. Neutral loss (asterisk) and internal fragments are annotated.(D) Schematic of NANOG with functional domains. Question marks denote phosphorylation sites that were indistinguishable between adjacent residues.See also [Figures S1](#app2){ref-type="sec"} and [S2](#app2){ref-type="sec"}, and [Table S1](#app2){ref-type="sec"}.

To place NANOG phosphorylation sites in the context of cell signaling, we used the Motif-X program to search for kinase motifs in our data set ([@bib24]). Intriguingly, a preponderance of NANOG's phosphorylation sites were proline directed (xP) and matched the minimal ERK motif (5/11 sites; [Figure 1](#fig1){ref-type="fig"}B) ([@bib28]). This finding is compelling from a biological standpoint because *NANOG* overexpression sustains pluripotency upon ERK inhibition ([@bib35]) and activation of ERK2 maintains NANOG, even in differentiating cells ([@bib39]). Further computational analysis using the NetPhorest platform substantiated the hypothesis that ERK2 phosphorylates these sites, but also pointed to CDK1 as a possible modifying enzyme ([@bib16]). Note that these kinases share similar motifs, and the importance of applying both experimental and computational methods to determine kinase-substrate relationships has been documented ([@bib14]). Thus, it is important to directly screen for the kinases that modify NANOG.

MAKS {#sec2.2}
----

To directly identify kinases that target specific residues on NANOG, we developed a mass-spectrometric approach called MAKS. This in vitro assay leverages isobaric tagging technology to monitor the activity of up to ten kinases in a single experiment. In the first step, candidate kinases, ATP, and reaction buffer are added to purified protein(s) in separate but otherwise identical reactions ([Figure 2](#fig2){ref-type="fig"}A). Following incubation, each sample is digested in preparation for mass spectrometry and labeled with a different isobaric tag. This tag imparts a unique chemical signature to every peptide, linking it to the kinase-substrate reaction from which it originated. Samples are combined and subjected to quantitative tandem mass spectrometry to directly identify peptide sequences and sites of phosphorylation. During peptide fragmentation, the isobaric tags are cleaved, generating reporter ions that are detected in the low-mass region of tandem mass spectra ([Figure 2](#fig2){ref-type="fig"}B). The intensity of these reporter ions functions as a readout for the abundance of phosphorylated peptides from the corresponding kinase reaction.Figure 2A Simplified Schematic for MAKS(A) Identical protein samples are treated separately with kinases, labeled, and mixed prior to analysis. A six-plex experiment is shown, but ten samples can be simultaneously assayed.(B) Peptide identity and phosphorylation site localization are determined using tandem mass spectrometry. Reporter tags are cleaved during tandem mass spectrometry and appear in the low-mass range (liftout). The relative intensity for each reporter tag is directly proportional to the amount of phosphorylation contributed by the corresponding kinase.

MAKS Reveals Site-Specific Phosphorylation by ERK2 and CDK1 on NANOG {#sec2.3}
--------------------------------------------------------------------

We selected AKT1, AKT2, CDK1/CyclinA2, CDK5/p35, ERK2, and PKA as candidate kinases for NANOG modification. We chose these kinases based primarily on motif analysis for phosphorylation sites on NANOG (ERK2 and CDK1/5), but also considered kinases involved in pluripotency and differentiation (AKT1/2 and PKA). This selection of kinases also covered candidates from both the AGC and CMCG kinase families. All kinases were active and capable of phosphorylating numerous control substrates ([Table S2](#mmc2){ref-type="supplementary-material"}). We therefore performed our in vitro assay by incubating each kinase with full-length, recombinant NANOG. Following mass spectrometry, reporter ion intensities were mean normalized and adjusted using nonphosphorylated peptides to correct for pipetting error and sample loss (see [Experimental Procedures](#sec4){ref-type="sec"}; [Figure S3](#app2){ref-type="sec"}A). In total, we quantified five phosphorylation sites, all of which corresponded to modifications on the endogenous protein ([Figures 3](#fig3){ref-type="fig"} and [S3](#app2){ref-type="sec"}B). As shown in [Figure 3](#fig3){ref-type="fig"}, ERK2 demonstrated a clear preference for Ser52, a putative ERK site that was also identified on the endogenous protein ([Figure 3](#fig3){ref-type="fig"}B). The abundance of phosphorylation for Ser52 was 5-fold higher for the ERK2 channel than for the next-closest channel. Interestingly, our data also showed that Ser71, another putative ERK site identified on endogenous NANOG, was instead preferentially phosphorylated by CDK1/CyclinA2 ([Figure 3](#fig3){ref-type="fig"}C), while Ser65 was modified by both ERK2 and CDK1/CyclinA2 ([Figure S3](#app2){ref-type="sec"}B). This demonstrates the remarkable specificity achieved through this simple assay and also illustrates the importance of determining phosphorylation for individual sites. Phosphorylation at Ser23 and Ser258 was similar across all kinases ([Figures 3](#fig3){ref-type="fig"}D and [S3](#app2){ref-type="sec"}B), suggesting that (1) a different kinase is responsible for phosphorylation at these sites, (2) cofactors not included in this assay are required for specificity, or (3) these sites can be phosphorylated by a variety of kinases. Importantly, this shows that the specificity observed at Ser52 and Ser71 is not the result of higher activity for the respective kinases. Phosphorylation sites that were identified on the endogenous protein but not quantified in the MAKS assay may be subject to regulation by kinases that were not included in our panel, or may require additional cofactors and/or subcellular localization.Figure 3ERK2 and CDK1 Specifically Phosphorylate Different Sites on NANOG(A) Mass spectrum from a typical kinase assay with Ser52 phosphorylation. Neutral loss (asterisk) is annotated. The liftout shows a zoomed view of the reporter ion region.(B) ERK2 preferentially phosphorylates Ser52.(C) CDK1 specifically phosphorylates Ser71.(D) No kinase tested shows a preference for Ser258. Bar graphs represent the normalized abundance of at least three PSMs. Error bars represent the SD calculated from at least three PSMs across three independent experiments. The dashed line indicates the level that would be expected if the contribution for all channels were equal.See also [Figure S3](#app2){ref-type="sec"} and [Table S2](#mmc2){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Together with OCT4 and SOX2, NANOG functions as a key transcriptional regulator in pluripotency. To date, almost no information is available regarding posttranslational regulation of NANOG. Our data show that NANOG is multiply phosphorylated in human ESCs. Nine of 11 sites were observed in a serine/threonine-rich patch from residues 50--79, suggesting that this region may serve as a regulatory cluster. In support of this notion, recent computational work identified a putative PEST sequence (residues 47--72) on NANOG that overlaps greatly with the hyperphosphorylated region ([Figure 1](#fig1){ref-type="fig"}D; [@bib22]). Deletion of the PEST sequence altered NANOG ubiquitination and degradation ([@bib22]). Further, mutational analysis in mouse for sites homologous to Ser52, Ser65, and Ser71 suggested that phosphorylation of these residues stabilizes NANOG ([@bib18]). All of these results point to a role for this region in regulating NANOG protein levels. Our data provide direct evidence that these regulatory sites are phosphorylated on human NANOG and in a physiological context. The function of phosphorylation at Ser22/23 and Ser258 is currently unclear; however, Ser258 is located in the CD2 activation domain and may modulate NANOG's ability to activate transcription ([@bib9]). Further work will be needed to clarify the exact role of each modification identified here.

For years, FGF has been a requisite component in human pluripotent stem cell media ([@bib6], [@bib15]), and yet the mechanism by which FGF supports pluripotency was unknown. Our data show that ERK2, a downstream effector in the FGF pathway, directly phosphorylates NANOG at Ser52. A recent report demonstrated that phosphorylation of a homologous site on mouse NANOG facilitated interaction with Pin1, a prolyl isomerase that inhibits ubiquitination and subsequent proteosomal degradation by inducing conformational changes ([@bib18]). Together, these data suggest that ERK2 phosphorylation positively regulates NANOG by increasing its stability. The interplay between ERK and CDK signaling is also interesting in the context of pluripotency. Our data show that these kinases phosphorylate similar sequences on NANOG that are separated by only 19 amino acids. This result raises the possibility that CDK1 functions analogously to ERK, perhaps to sustain NANOG during S/M phase; however, this is only speculative at this point.

MAKS provides a multiplexed strategy for simultaneously screening multiple kinases and protein substrates. A major advantage of this assay is its capacity to directly assess kinase activity for individual phosphorylation sites. In the case of NANOG, this feature enabled us to dissect the specificity of ERK2 and CDK1/CyclinA2, even on nearby sites. This specificity may result from three-dimensional protein structure or cooperation with CyclinA2, although it is also possible that the primary sequence alone is sufficient to direct kinase activity. In this regard, a further benefit of MAKS is that it allows one to carry out kinase assays using whole proteins as a substrate. This preserves a potential phosphorylation site in the context of adjacent residues or protein structure. Other cofactors, subcellular localization, or additional modifications may be necessary to confer specificity. MAKS provides a means to test the role of many of these additional components, which can be added or removed from the kinase reaction to determine their effect. The multiplexing capacity is only limited by the number of isobaric tags available from the manufacturer (currently ten tags are commercially available), and because substrates are directly identified via mass spectrometry, multiple proteins of interest can be analyzed in a single reaction.

We note that the MAKS assay applies relative quantitation and therefore requires careful selection of candidate kinases. In some instances, for example, a physiological kinase for a given substrate may be absent from the panel tested. In such cases, MAKS will identify the kinase that exhibits the highest activity for a given substrate, if indeed there is a preference among the kinases tested. Computational methods will be critical for selecting the most likely candidate kinases, and testing a wide variety of kinases should help in identifying the most relevant kinases. To this end, we are currently working to couple kinase panels to automated mass spectrometry to increase the throughput of the MAKS assay and expand the number of kinases that can be tested to hundreds of kinases. The MAKS approach should also be applicable to any protein-modifying enzyme (i.e., acetylase, methyltransferase, etc.). Together, the simplicity and multiplexing capabilities of this assay make MAKS widely applicable in screening for enzymes that modify a substrate of interest.

Experimental Procedures {#sec4}
=======================

Kinase Assays {#sec4.1}
-------------

Kinase assays were carried out in 25 mM MOPS, pH 7.2, 12.5 mM beta-glycerol-phosphate, 25 mM MgCl~2~, 5 mM EGTA, 2 mM EDTA, 1 mM dithiothreitol (DTT), and 0.1 mM ATP. Approximately 1 μg of recombinant NANOG and 0.25 μg of AKT1, AKT2, CDK1, CDK5, or ERK2 (all from Promega), or 2.5 U of PKA (Sigma) were added for 30 min at 23°C. For control reactions, 0.5 μg of maltose-binding protein (MBP) and histone H1 (SignalChem) were added in place of NANOG. The reactions were then treated with 5 mM DTT at 37°C for 30 min, 10 mM iodoacetamide in the dark at 23°C for 30 min, and 10 mM DTT at 23°C for 30 min. Proteins were digested with GluC or chymotrypsin (both from Roche Diagnostics) at an enzyme-to-protein ratio of 1:200, purified by solid-phase extraction, and labeled with TMT isobaric tags (Thermo-Fisher) according to the manufacturer's recommendations.

Data analysis {#sec4.2}
-------------

Phosphosite localization was evaluated using Phosphinator software ([@bib29]). This algorithm processes the theoretical fragment ion *m/z* ratios for all possible permutations of phosphopeptide isoforms based on sequence and the number of phosphorylation sites. It then compares each experimental spectrum to the theoretical product ions using a product mass tolerance of ± 0.02 Th. Phosphinator determines the significance of observed product ions that designate phosphorylation at a given amino acid. A localized site must have a p value of \<0.05 for consideration. Further details about this algorithm were previously described ([@bib29]). Each localized phosphosite reported by Phosphinator was manually validated. Other high-scoring spectra with unlocalized phosphosites (as reported by Phosphinator) were manually interrogated to determine whether localization could be achieved. Theoretical product ions from other candidate phospho-isoforms were generated using the MS Product program in Protein Prospector (<http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct>), and localization and spectral chimerism were evaluated ([@bib7]). In all cases, product ions were required to be within 15 ppm of the theoretical *m/z* with a signal-to-noise ratio ≥ 3 to be used for sequence assignment. Both neutral loss product ions and internal fragments were considered during manual validation in addition to standard b- and y-type ions (HCD) and c- and z-type product ions (ETD).

TMT isotope purity corrections were applied using the TagQuant program in COMPASS ([@bib33]). Purity-corrected tag intensities were mean normalized for all peptide spectral matches (PSMs). We then took advantage of *E. coli* proteins that copurified with recombinant NANOG to further correct for pipetting error and sample loss. Briefly, *E. coli* PSMs were filtered to eliminate any peptide hit that contained a potential phosphorylation site (STY) or exhibited greater than 25% interference. The values for each channel were then averaged to establish the mean bias for that channel. Dividing one by each mean bias generated correction factors, which were used to normalize the quantitative values for each channel.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S3, and Table S1Table S2. Phosphopeptides, \<1% False Discovery Rate, from Control Substrates, Related to Figure 3
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